Literature DB >> 31196358

eIF6 Promotes Colorectal Cancer Proliferation and Invasion by Regulating AKT-Related Signaling Pathways.

Jinxin Lin, Xihu Yu, Liping Xie, Puning Wang, Tuoyang Li, Yuanlv Xiao, Jiaming Zhou, Shaoyong Peng, Jun Huang, Yanxin Luo, Meijin Huang, Jianping Wang.   

Abstract

Although abnormal expression of eukaryotic initiation factor 6 (eIF6) has been found in several human solid tumors, the functions and underlying mechanisms of eIF6 in the progression of colorectal cancer (CRC) still needs further elucidation. In the present study, large-scale gene analysis based on Oncomine and The Cancer Genome Atlas (TCGA) database revealed significantly higher baseline expression of eIF6 in colorectal cancer than in normal tissues. Furthermore, our Chinese cohort study revealed that high expression of eIF6 was correlated with aggressive characteristics and poor survival in CRC patients. Functional studies using magnetic nanoparticle extraction indicated that eIF6 was an oncogene in CRC cells. Regarding its mechanism, through Gene ontology (GO) and KEGG pathway analysis based on TCGA RNAseq database, we found that eIF6 can activate multiple AKT-related cancer signaling pathways, such as p-AKT\MMP1\cyclinD1\Bcl2-related signaling, to regulate cell proliferation, invasion, cell cycle and apoptosis in CRC. Collectively, these findings suggested that eIF6 can positively regulate AKT-related cancer signaling and enhance tumorigenicity in CRC, and may serve as a potential prognostic indicator and therapeutic target in CRC.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31196358     DOI: 10.1166/jbn.2019.2792

Source DB:  PubMed          Journal:  J Biomed Nanotechnol        ISSN: 1550-7033            Impact factor:   4.099


  7 in total

1.  Diagnostic and prognostic utility of eIF6 in glioblastoma: a study based on TCGA and CGGA databases.

Authors:  Jian Liang; Fengyu Liu; Yaoqiang Yang; Xing Li; Guangmou Cai; Jianxuan Cao; Bo Zhang
Journal:  Am J Transl Res       Date:  2022-07-15       Impact factor: 3.940

2.  eIF6 is potential diagnostic and prognostic biomarker that associated with 18F-FDG PET/CT features and immune signatures in esophageal carcinoma.

Authors:  Yan Gao; Lingling Yuan; Jing Zeng; Fuyan Li; Xiaohui Li; Fan Tan; Xusheng Liu; Huabing Wan; Xueyan Kui; Xiaoyu Liu; Changbin Ke; Zhijun Pei
Journal:  J Transl Med       Date:  2022-07-06       Impact factor: 8.440

3.  eIF6 as a Promising Diagnostic and Prognostic Biomarker for Poorer Survival of Cutaneous Melanoma.

Authors:  Fangyingnan Zhang; Saquib Waheed; Ubaldo Armato; Jun Wu; Chao Zhang; Zhibin Li
Journal:  Front Oncol       Date:  2022-05-30       Impact factor: 5.738

4.  eIF6 promotes the malignant progression of human hepatocellular carcinoma via the mTOR signaling pathway.

Authors:  Liping Sun; Shuguang Liu; Xiaopai Wang; Xuefeng Zheng; Ya Chen; Hong Shen
Journal:  J Transl Med       Date:  2021-05-20       Impact factor: 5.531

5.  Cytoplasmic eIF6 promotes OSCC malignant behavior through AKT pathway.

Authors:  Zechen Zhao; Weiming Chu; Yang Zheng; Chao Wang; Yuemei Yang; Teng Xu; Xueming Yang; Wei Zhang; Xu Ding; Gang Li; Hongchuang Zhang; Junbo Zhou; Jinhai Ye; Heming Wu; Xiaomeng Song; Yunong Wu
Journal:  Cell Commun Signal       Date:  2021-12-18       Impact factor: 5.712

6.  Small Interfering RNA in Colorectal Cancer Liver Metastasis Therapy.

Authors:  Junlin Xie; Shubin Wang
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

7.  Long noncoding RNA PICSAR/miR-588/EIF6 axis regulates tumorigenesis of hepatocellular carcinoma by activating PI3K/AKT/mTOR signaling pathway.

Authors:  Zhikui Liu; Huanye Mo; Liankang Sun; Liang Wang; Tianxiang Chen; Bowen Yao; Runkun Liu; Yongshen Niu; Kangsheng Tu; Qiuran Xu; Nan Yang
Journal:  Cancer Sci       Date:  2020-09-23       Impact factor: 6.716

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.